WHO ICTRP trial
A Study of Disitamab Vedotin Alone or with Other Anticancer Drugs in Solid…
CTIS2023-507555-29-00 · EU Clinical Trials Information System · Recruiting
Key facts
| Trial ID | CTIS2023-507555-29-00 |
|---|---|
| Public title | A Study of Disitamab Vedotin Alone or with Other Anticancer Drugs in Solid Tumors |
| Scientific title | A Phase 1b/2 Open-Label Study of Disitamab Vedotin Monotherapy or in Combination with Other Anticancer Therapies in Solid Tumors - SGNDV-004 |
| Primary sponsor | Seagen Inc. |
| Registry | EU Clinical Trials Information System |
| Recruitment status | Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): Yes Therapeutic exploratory (Phase II): Yes Therapeutic confirmatory - (Phase III): No Therapeutic use - (Phase IV): No |
| Countries | United States;Japan;United Kingdom;Taiwan;Australia;Canada;Korea, Republic of;France;Germany;Italy;Spain |
| Conditions | LA/mGC/GEJC (locally advanced unresectable or metastatic gastric cancer and gastroesophageal junction adenocarcinoma, collectively) and LA/mBC (locally advanced metastatic breast cancer) MedDRA version: 23.0Level: PTClassification code… |
| Interventions | Product Name: Disitamab Vedotin, Product Code:PRD9442609, Pharmaceutical Form: POWDER FOR SOLUTION FOR INFUSION, Other descriptive name: , Strength: , Product Name: TUKYSA 150 mg film-coated tablets, Product Code:PRD8771193, Pharmaceutical… |
| Registration date | Feb 15, 2024 |
| Target size | 371 |
| Registry page | euclinicaltrials.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: